Available online on 15.03.2023 at http://jddtonline.info

Journal of Drug Delivery and Therapeutics

Open Access to Pharmaceutical and Medical Research

Copyright  © 2023 The  Author(s): This is an open-access article distributed under the terms of the CC BY-NC 4.0 which permits unrestricted use, distribution, and reproduction in any medium for non-commercial use provided the original author and source are credited

Open Access  Full Text Article                                                                                                                                                                                               Research Article

Novel 1, 3, 4-Oxadiazole-pyridine hybrids as potential DNA gyrase B inhibitors (5D7R): ADMET prediction and molecular docking study

Nagaraj N Durgadasheemi*[1], Shivanand N Kolageri*2

1 Department of Pharmaceutical Chemistry, R R College of Pharmacy, Chikkabanavar, Bengaluru-560090 Karnataka, India

2 Department of Pharmaceutical Chemistry, BLDEA’s SSM College of Pharmacy and Research Centre, Vijayapur-586103, Karnataka, India

Article Info:

__________________________________________

Article History:

Received 02 Jan 2023     

Reviewed  11 Feb 2023

Accepted 17 Feb 2023 

Published 15 March 2023 

__________________________________________

Cite this article as:

Durgadasheemi NN, Kolageri SN, Novel 1, 3, 4-Oxadiazole-pyridine hybrids as potential DNA gyrase B inhibitors (5D7R): ADMET prediction and molecular docking study, Journal of Drug Delivery and Therapeutics. 2023; 13(3):12-19

DOI: http://dx.doi.org/10.22270/jddt.v13i3.5749                    

Abstract

________________________________________________________________________________________________________________________

A small molecule (ligand) is placed in the binding site of its macromolecular target (receptor) using a computational process called molecular docking, which also calculates the binding affinity of the small molecule. With the use of PyRx software, the current study tried a high-throughput in-silico screening of 16 compounds docked with the crystal structure of DNA gyrase B receptors (PDB ID: 5D7R). In the range of -8.0 and -8.1, 3 of these 16 compounds displayed very good mol dock scores. As a typical medicine, amoxicillin medications have a mol dock score of -7.1. According to the results, all of the investigated ligands occupy similar positions and directions within the putative binding site of DNA gyrase B receptors (PDB ID: 5D7R), which reveals a sizable area surrounded by a membrane binding domain that acts as a pathway for substrate entry into the active site. Additionally, any small molecule's affinity can be viewed as a special instrument in the field of drug design and provide a possibility for future study to create an antibacterial activity. Additionally, ADME evaluations must be used to confirm compounds that are candidates for oral administration. The findings demonstrated that compound 4a, 4b, 4c, 4d, 4i, 4j, and 4k absorbed from GIT and compound 4i, 4j, and 4k fulfilled the Lipinski rule.

Keywords: 1, 3, 4-Oxadiazole, ADME Evaluation, molecular docking, antimicrobial activity

 

INTRODUCTION:

Traditional methods for finding innovative therapeutic medicines were very expensive, time-consuming, and possibly less effective. Virtual screening, supported by the presentation of structural information, is a rational and straightforward strategy that is introduced to solve the shortcomings of existing strategies. Virtual screening techniques are frequently categorised as structure- and ligand-based drug design methodologies. While ligand-based tactics address quantitative structure activity relationship (QSAR) and pharmacophore modelling, the structure-based drug approach discusses molecular tying up 1. The molecular docking method determines how a chemical interacts with a target molecule. By identifying the preferred orientation of the least free energy, it predicts the affinity of molecules for binding to form a stable complex with the supermolecule 2. For the most part, Shape Complementarity and Simulation are the two fundamental techniques used in molecular docking.

 

Figure 1 Computer-aided drug design

 

1,3,4‐Oxadiazole is a 5‐membered planar aromatic group represents affluent heterocyclic group and its derivatives have played a major role in the pharmaceutical chemistry. 1,3,4-Oxadiazole derivatives are the heterocyclic that have received considerable attention during the last two decades as they possess wide range of biological properties include antibacterial3, antituberculosis4, anti‐inflammatory5, antifungal6, analgesic7, anticancer8, immunosuppressive9, anticonvulsant10], and tyrosinase inhibitor.11

MATERIALS AND METHODS:

Software required:

The study of molecular docking was conducted on a computer equipped with the computational tools swiss dock, PyRx, and Biovia discovery studio visualizer tools (HP Pavilion AMD RyzenTM 5 Hexa Core 5500 APU @ 2.1GHz with turbo boost up to 4GHz Processor version 5500U and 16.00 GB RAM with 64-bit Windows-11 operating system).

Ligand and macromolecule preparation:

The chemical structures of the ligands utilised in this work were created and optimised using the free Chemsketch 2021 programme, and they were stored in mol format before being translated to PDB format by Open Bable 2.3.2, which was necessary for PyRx software execution. Before beginning the molecular docking procedure, the target enzyme was prepped by removing the natural ligand and water molecules that were linked to it. After that, the investigation ligand was loaded with hydrogen atoms added, their torsions and rotatable bonds were assigned, and the files were saved as ligand pdbqt.

 

Figure. No: 2

R-

-H

2-OCH3

3-Cl

4-NO2

2-CH3

3-OCH3

4-Cl

2-OH

3-CH3

4-OCH3

2-NO2

3-OH

4-CH3

2-Cl

3-NO2

4-OH

 

Ligand Identification:

The ligands were 1,3,4-oxadiazole derivatives (Table-2). Azithromycin, ciprofloxacin, and amoxicillin are some of the contemporary antibacterial medications. They were obtained from the drug bank database and used in comparison and docking investigations (Table-1). The Open Babel application was used to download the known structures in SDF format and convert them to PDB format. The next step was to conduct docking research using PyRx and the Biovia Discovery Studio visualizer tools.

In silico ADME (Absorption, Distribution, Metabolism and Excretion Studies):

ADME describes the pharmacokinetics of substances in an organism's body. It assesses the danger associated with administering a pharmaceutical substance to an individual or another creature. Pre ADMET (https://preadmet.bmdrc.kr/), Swiss ADME (http://www.swissadme.ch/), and other online tools are used to identify these pharmacokinetic features in silico. The molecules become inactive when there are two or more violations of Lipinski's rule of five. To assess whether a molecule is similar to existing drugs on the market, a complex balancing act involving several chemical properties and structural traits must be performed.

In this way, the 16 different conformers were generated (Figure-2) and blind docking was performed to know whether these molecules bind in the active site or anywhere in the target was demonstrated by the biovia discovery studio program.

 

 

 

Table-1 Showing Structure and Standard of known drug.

Sl.No.

Ligand

PubChem CID

Structures

1

amoxicillin

33613

 

 

 

 

 

 

 

 

Table-2 Showing structures of 1,3,4-oxadiazole derivatives used as ligands. (4a-4p)

Ligand code

IUPAC /Ligand name

Structures

4a

1-[5-(6-methylpyridin-3-yl)-2-phenyl-1,3,4-oxadiazol-3(2H)-yl]ethan-1-one

 

 

4b

1-[2-(2-methylphenyl)-5-(6-methylpyridin-3-yl)-1,3,4-oxadiazol-3(2H)-yl]ethan-1-one

 

 

4c

1-[2-(3-methylphenyl)-5-(6-methylpyridin-3-yl)-1,3,4-oxadiazol-3(2H)-yl]ethan-1-one

 

 

4d

1-[2-(4-methylphenyl)-5-(6-methylpyridin-3-yl)-1,3,4-oxadiazol-3(2H)-yl]ethan-1-one

 

 

4e

1-[2-(2-methoxyphenyl)-5-(6-methylpyridin-3-yl)-1,3,4-oxadiazol-3(2H)-yl]ethan-1-one

 

 

4f

1-[2-(3-methoxyphenyl)-5-(6-methylpyridin-3-yl)-1,3,4-oxadiazol-3(2H)-yl]ethan-1-one

 

 

4g

1-[2-(4-methoxyphenyl)-5-(6-methylpyridin-3-yl)-1,3,4-oxadiazol-3(2H)-yl]ethan-1-one

 

 

4h

1-[2-(2-chlorophenyl)-5-(6-methylpyridin-3-yl)-1,3,4-oxadiazol-3(2H)-yl]ethan-1-one

 

 

4i

1-[2-(3-chlorophenyl)-5-(6-methylpyridin-3-yl)-1,3,4-oxadiazol-3(2H)-yl]ethan-1-one

 

 

4j

1-[2-(4-chlorophenyl)-5-(6-methylpyridin-3-yl)-1,3,4-oxadiazol-3(2H)-yl]ethan-1-one

 

 

4k

1-[5-(6-methylpyridin-3-yl)-2-(2-nitrophenyl)-1,3,4-oxadiazol-3(2H)-yl]ethan-1-one

 

 

4l

1-[5-(6-methylpyridin-3-yl)-2-(3-nitrophenyl)-1,3,4-oxadiazol-3(2H)-yl]ethan-1-one

 

 

4m

1-[5-(6-methylpyridin-3-yl)-2-(4-nitrophenyl)-1,3,4-oxadiazol-3(2H)-yl]ethan-1-one

 

 

4n

1-[2-(2-hydroxyphenyl)-5-(6-methylpyridin-3-yl)-1,3,4-oxadiazol-3(2H)-yl]ethan-1-one

 

 

4o

1-[2-(3-hydroxyphenyl)-5-(6-methylpyridin-3-yl)-1,3,4-oxadiazol-3(2H)-yl]ethan-1-one

 

4p

1-[2-(4-hydroxyphenyl)-5-(6-methylpyridin-3-yl)-1,3,4-oxadiazol-3(2H)-yl]ethan-1-one

 

 

 

 


RESULTS AND DISCUSSION:

Absorption, distribution, metabolism and excretion (ADME results:

We can say that the molecules are orally active because all the created compounds adhere to the same rule. Tables 3 and 4 present the findings of ADME investigations. The octanol water partition coefficient (mol log P) of the proposed compounds must not be larger than 5. The compounds' good oral bioavailability is indicated (Table 3). The logarithm of molar concentration is used to represent the water solubility. The usual range for the skin permeability of designed compounds is between -5.50 to -6.07 cm/s. The suggested compounds are only moderately water-soluble because they have lipophilic functionalities intended to increase cell permeability. Using a volume of distribution, blood-brain barrier permeability, and fraction unbound, the drug's distribution in the body was estimated. A higher value for the volume of distributions denotes a better drug distribution in tissues compared to plasma, and a log volume of distributions value greater than 0.40 denotes a greater tissue distribution.

 

 

 

 

 

 

Table-3: Drug likeness analysis of designed 1,3,4-Oxadiazole derivatives (4a-4p)

Comp

Code

 

Physicochemical Properties

Lipinski Rule

%Absd

MR

N

rotf

R

MWa

TPSAb

milogPc

HA

HD

4a

H

281.31 54.79

2.37

4

0

Yes

90.09

86.07

3

4b

2-CH3

295.34

54.79

2.62

4

0

Yes

90.09

91.04

3

4c

3-CH3

295.34

54.79

2.62

4

0

Yes

90.09

91.04

3

4d

4-CH3

295.34

54.79

2.62

4

0

Yes

90.09

91.04

3

4e

2-OCH3

311.34

64.02

2.07

5

0

Yes

86.91

92.56

4

4f

3-OCH3

311.34

64.02

2.07

5

0

Yes

86.91

92.56

4

4g

4-OCH3

311.34

64.02

2.07

5

0

Yes

86.91

92.56

4

4h

2-Cl

315.75

54.79

2.89

4

0

Yes

90.09

91.08

3

4i

3-Cl

315.75

54.79

2.89

4

0

Yes

90.09

91.08

3

4j

4-Cl

315.75

54.79

2.89

4

0

Yes

90.09

91.08

3

4k

2-NO2

326.31

100.61

2.26

6

0

Yes

74.28

94.89

4

4l

3-NO2

326.31

100.61

2.26

6

0

Yes

74.28

94.89

4

4m

4-NO2

326.31

100.61

2.26

6

0

Yes

74.28

94.89

4

4n

2-OH

352.42

75.02

1.83

5

1

Yes

83.11

88.09

3

4o

3-OH

352.42

75.02

1.83

5

1

Yes

83.11

88.09

3

4p

4-OH

297.31

75.02

1.83

5

1

Yes

83.11

88.09

3

                       

aMW: molecular weight, bTPSA: total polar surface area, cmiLogP: molinspiration partition coefficient, d%Abs: %Abs = 109 − (0.345 × TPSA), enviol: number of violations, fnrotb: number of rotatable bonds, HA: number of hydrogen bond acceptors, HD: number of hydrogen bond donors.

 

Table-4: In silico ADME properties of 1,3,4-Oxadiazole designed derivatives. (4a-4p)

Comp.Code

R

Intestinal absorption (%absorbed)

CYP1A2 inhibitor

CYP2C19 inhibitor 

CYP2C9 inhibitor

CYP2D6 inhibitor 

CYP3A4 inhibitor

Log Kp (skin permeation)

(cm/s)

4a

-H

High

No

Yes

Yes

No

No

-6.40

4b

2-CH3

High

No

Yes

Yes

No

No

-6.23

4c

3-CH3

High

No

Yes

Yes

No

No

-6.23

4d

4-CH3

High

No

Yes

Yes

No

No

-6.23

4e

2-OCH3

High

No

Yes

Yes

No

No

-6.61

4f

3-OCH3

High

No

Yes

Yes

No

No

-6.61

4g

4-OCH3

High

No

Yes

Yes

No

No

-6.61

4h

2-Cl

High

No

Yes

Yes

No

No

-6.17

4i

3-Cl

High

No

Yes

Yes

No

 No

-6.17

4j

4-Cl

High

No

Yes

Yes

No

No

-6.17

4k

2-NO2

Low

No

Yes

Yes

No

No

-6.80

4l

3-NO2

Low

No

Yes

Yes

No

No

-6.80

4m

4-NO2

Low

No

Yes

Yes

No

No

-6.80

4n

2-OH

High

No

No

No

No

No

-6.75

4o

3-OH

High

No

No

No

No

No

-6.75

4p

4-OH

High

No

No

No

No

No

-6.75

 

 

 


Molecular docking results:

The target antibacterial drug discovery In-silico docking study of 16 compounds gave us an idea about the derivatives responsible for anti-microbial activity. The obtained results indicated that all studied ligands have similar positions and orientation inside the putative binding site of crystal structure DNA gyrase B receptors or (PDB ID: 5D7R) which reveals a large space bounded by a membrane-binding domain which serves as an entry channel for substrate to the active site. In addition, the affinity of any small molecule can be considered as a unique tool in the field of drug design. There is a relationship between the affinity of organic molecules and the free energy of binding. This relationship can contribute in the prediction and interpretation of the activity of the organic compounds toward the specific target protein and may be the possible mechanism by which derivatives displayed their anti-microbial activity as on this protein constituent are most appropriately docked.

Based on the docking binding score of the 4m and 4n compounds has resulted in a good binding affinity score of -8.1kcal/mol in comparison to the other derivatives and also it exhibited that activity approx. nearly with the standard drug amoxicillin of -7.11kcal/mol. The same 5D7R protein has interacted with the 4m and 4n compounds in comparison with standard amoxicillin drugs having better therapeutic activity. The various residues of amino acids (e.g., ILE175, ILE51, GLU58, ILE86, SER55, ASP51, PRO87, ARG84, ARG144, GLY85, GLU58,) have interacted with the 4m and 4n scaffolds. The standard amoxicillin has interacted similarly with some of the amino acid residues (ARG84, SER55, GLU58, ILE86, ILE179).

 

 

 

Table-5: Docking score of the designed 1,3,4-Oxadiazole derivatives.

Comp. Code

R

Molecular formula

Molecular weight

Rmsd/ub

Rmsd/lb

Docking Score (kcal/mol)

4a

-H

C12H15N3O2

281.30

0

0

-7.3

4b

2-CH3

C17H17N3O2

295.33

0

0

-7.7

4c

3-CH3

C17H17N3O2

295.33

0

0

-7.7

4d

4-CH3

C17H17N3O2

295.33

0

0

-7.6

4e

2-OCH3

C17H17N3O3

311.33

0

0

-7.6

4f

3-OCH3

C17H17N3O3

311.33

0

0

-7.5

4g

4-OCH3

C17H17N3O3

311.33

0

0

-7.4

4h

2-Cl

C16H14ClN3O2

315.75

0

0

-7.7

4i

3-Cl

C16H14ClN3O2

315.75

0

0

-7.6

4j

4-Cl

C16H14ClN3O2

315.75

0

0

-7.5

4k

2-NO2

C16H14N4O4

326.30

0

0

-7.8

4l

3-NO2

C16H14N4O4

326.30

0

0

-8.0

4m

4-NO2

C16H14N4O4

326.30

0

0

-8.1

4n

2-OH

C16H15N3O3

297.30

0

0

-8.1

4o

3-OH

C16H15N3O3

297.30

0

0

-7.5

4p

4-OH

C16H15N3O3

297.30

0

0

-7.4

amoxicillin

C16H19N3O5S

365.4

0

0

-7.1

 

 

Fig.3: 3D structure of amoxicillin interacts with DNA gyrase B inhibitors (5D7R)

 

Fig.4: 3D structure of amoxicillin, hydrogen bond interaction with DNA gyrase B inhibitors (5D7R)

 

Fig.5: 3D structure of amoxicillin, hydrophobicity interaction with DNA gyrase B inhibitors (5D7R)

 

Fig.6: 2D structure of amoxicillin interaction with DNA gyrase B inhibitors (5D7R)

 

 

Fig.7: 3D structure of 1-[5-(6-methylpyridin-3-yl)-2-(4-nitrophenyl)-1,3,4-oxadiazol-3(2H)-yl]ethan-1-one interacts with DNA gyrase B inhibitors (5D7R)

 

Fig.8: 3D structure of 1-[5-(6-methylpyridin-3-yl)-2-(4-nitrophenyl)-1,3,4-oxadiazol-3(2H)-yl]ethan-1-one, hydrogen bond interaction with DNA gyrase B inhibitors (5D7R)

 

Fig.9: 3D structure of 1-[5-(6-methylpyridin-3-yl)-2-(4-nitrophenyl)-1,3,4-oxadiazol-3(2H)-yl]ethan-1-one, hydrophobicity interaction with DNA gyrase B inhibitors (5D7R)

Fig.10: 2D structure of interaction 1-[5-(6-methylpyridin-3-yl)-2-(4-nitrophenyl)-1,3,4-oxadiazol-3(2H)-yl]ethan-1-one with DNA gyrase B inhibitors (5D7R)

 

 

Fig.11: 3D structure of 1-[2-(2-hydroxyphenyl)-5-(6-methylpyridin-3-yl)-1,3,4-oxadiazol-3(2H)-yl]ethan-1-one interacts with DNA gyrase B inhibitors (5D7R)

 

Fig.12: 3D structure of 1-[2-(2-hydroxyphenyl)-5-(6-methylpyridin-3-yl)-1,3,4-oxadiazol-3(2H)-yl]ethan-1-one, hydrogen bond interaction with DNA gyrase B inhibitors (5D7R)               

 

Fig.13: 3D structure of 1-[2-(2-hydroxyphenyl)-5-(6-methylpyridin-3-yl)-1,3,4-oxadiazol-3(2H)-yl]ethan-1-one, hydrophobicity interaction with DNA gyrase B inhibitors (5D7R)

 Fig.14: 2D structure of 1-[2-(2-hydroxyphenyl)-5-(6-methylpyridin-3-yl)-1,3,4-oxadiazol-3(2H)-yl]ethan-1-one, hydrogen bond interaction with DNA gyrase B inhibitors (5D7R)

 


Acknowledgement: The authors are thankful to Principal “Department of Pharmaceutical Chemistry” R R College of Pharmacy, Chikkabanavar, Bengaluru-560090 Karnataka and BLDEA’s SSM College of Pharmacy and Research Centre, Vijayapur-586103, Karnataka for encouraging throughout the research work.

Conflict of Interest: The authors declare that no financial or commercial ties that might be viewed as creating a conflict of interest existed throughout the research.

AUTHOR CONTRIBUTION:

Nagaraj N Durgadasheemi and Shivanand N Kolageri both did a proper literature survey, collected data, design the work, and wrote a portion of paper and provided maximum effort in the correction, both did a proper design the manuscript. Shivanand N Kolageri Conceived and design the analysis. The final draft was checked by all the authors. 

REFERENCES:

  1. Sliwoski G, Kothiwale S, Meiler J, Lowe EW. Computational methods in drug discovery. Pharmacological reviews. 2014 Jan 1; 66(1):334-95. https://doi.org/10.1124/pr.112.007336
  2. Jangra S, Kumar S, Choudhary M. Molecular docking studies of 1, 3, 4 oxadiazoles Derivatives as anti-convulsive agents. World Journal of Advanced Research and Reviews. 2020; 8(1):151-79. https://doi.org/10.30574/wjarr.2020.8.1.0381
  3. Yurttaş L, Bülbül EF, Tekinkoca S, Demirayak Ş. Antimicrobial activity evaluation of new 1,3,4-oxadiazole derivatives. Acta Pharm Sci. 2017; 55(2):45-54. https://doi.org/10.23893/1307-2080.APS.05511
  4. Macaev, F.et al., R: Synthesis of Novel 5-aryl-2- thio-1,3,4-oxadiazoles and the Study of Their Structure-Anti-Mycobacterial Activities Bioorg Med Chem 2005; 13:4842. https://doi.org/10.1016/j.bmc.2005.05.011
  5. Abd-Ellah SH, Abdel-Aziz M, Shoman ME, Beshr EAM, Kaoud TS, Ahmed ASFF. New 1,3,4- oxadiazole/oxime hybrids: Design, synthesis, anti-inflammatory, COX inhibitory and ulcerogenic liability. Bioorg Chem. 2017; 74:15- 29. https://doi.org/10.1016/j.bioorg.2017.06.003
  6. Zou, X. J.; Lai, L. H.; Jin, G. Y.; Zhang, Z. X. Synthesis, Fungicidal Activity, and 3D-QSAR of Pyridazinone-Substituted 1,3,4-oxadiazoles and 1,3,4-thiadiazoles J Agric Food Chem 2002; 50:3757 https://doi.org/10.1021/jf0201677
  7. Palaska E, Sahin G, Kelicen, P Durlu N. T, Altinok, G. Synthesis and anti-inflammatory activity of 1-acylthiosemicarbazides, 1,3,4- oxadiazoles, 1,3,4-thiadiazoles and 1,2,4-triazole-3-thiones. Farmacoterapia 2002; 57:101. https://doi.org/10.1016/S0014-827X(01)01176-4
  8. Bajaj S, Roy PP, Singh J. Synthesis, thmynidine phosphorylase inhibitory and computational study of novel 1,3,4-oxadizole-2-thione derivatives as a potential anticancer agent. Comput Biol Chem. 2018; 74:151-160. https://doi.org/10.1016/j.compbiolchem.2018.05.013
  9. Ryng S, Zimecki M, Jezierska-Mazzarello A, Panek JJ, Mączyński M, et al. A complex study of 5-amino-3-methyl-4-[2-(5-amino-1,3,4- oxadiazolo)]-isoxazole monohydrate: A new low-molecular-weight immune response modifier. Journal of Molecular Structure 2011; 999:60-67. https://doi.org/10.1016/j.molstruc.2011.05.031
  10. Zarghi A, Tabatabai S. A, Faizi M, Ahadian A, Navabi P, Zanqaneh V, Shafiee A. Z. Synthesis and Anticonvulsant Activity of New 2- substituted-5-(2-benzyloxyphenyl)-1,3,4- oxadiazoles. Bioorg Med Chem Lett 2005; 15:863 https://doi.org/10.1016/j.bmcl.2005.02.014
  11. Khan M. T, Choudhary M. I, Khan K. M, Rani M, Atta‐ur‐Rahman. Structure-activity Relationships of Tyrosinase Inhibitory Combinatorial Library of 2,5-disubstituted-1,3,4- oxadiazole Analogues. Bioorg Med Chem 2005; 13:3385 https://doi.org/10.1016/j.bmc.2005.03.012
  12. Ibrahim TS, Almalki AJ, Moustafa AH, Allam RM, Abuo-Rahma GE, El Subbagh HI, Mohamed MF. Novel 1, 2, 4-oxadiazole-chalcone/oxime hybrids as potential antibacterial DNA gyrase inhibitors: Design, synthesis, ADMET prediction and molecular docking study. Bioorganic Chemistry. 2021 Jun 1; 111:104885. https://doi.org/10.1016/j.bioorg.2021.104885
  13. Jadhav GR, Deshmukh DG, Medhane VJ, Gaikwad VB, Bholay AD. 2, 5-Disubstituted 1, 3, 4-oxadiazole derivatives of chromeno [4, 3-b] pyridine: Synthesis and study of antimicrobial potency. Heterocyclic Communications. 2016 Jun 1; 22(3):123-30. https://doi.org/10.1515/hc-2015-0215
  14. Gaonkar SL, Rai KL, Prabhuswamy B. Synthesis and antimicrobial studies of a new series of 2-{4-[2-(5-ethylpyridin-2-yl) ethoxy] phenyl}-5-substituted-1, 3, 4-oxadiazoles. European journal of medicinal chemistry. 2006 Jul 1; 41(7):841-6. https://doi.org/10.1016/j.ejmech.2006.03.002
  15. Farghaly AA, Vanelle P, El-Kashef HS. Synthesis, reactions and antimicrobial activity of some new 1, 3, 4-oxadiazoles, 1, 2, 4-triazoles and 1, 3, 4-thiadiazines derived from pyrazole. Heterocyclic Communications. 2005 Aug 1; 11(3-4):255-62. https://doi.org/10.1515/HC.2005.11.3-4.255
  16. Aghekyan АА, Mkryan GG, Panosyan HA, Safaryan AS, Stepanyan HM. Synthesis and Antibacterial Activity of Novel (4-Methoxyphenyl)-tetrahydropyranyl-substituted 1, 3, 4-Oxadiazoles. Russian Journal of Organic Chemistry. 2020 Feb; 56:281-6. https://doi.org/10.1134/S1070428020020177
  17. Bakavoli M, Rahimizadeh M, Shiri A, Eshghi H, Vaziri-Mehr S, Pordeli P, Nikpour M. Synthesis and evaluation of antibacterial activity of new derivatives of pyrimido [4, 5-e][1, 3, 4] oxadiazine. Heterocycl. Commun., 2011; 17(1-2):49-52. https://doi.org/10.1515/hc.2011.009
  18. Ningaiah S, Bhadraiah UK, Doddaramappa SD, Keshavamurthy S, Javarasetty C. Novel pyrazole integrated 1, 3, 4-oxadiazoles: Synthesis, characterization and antimicrobial evaluation. Bioorganic & medicinal chemistry letters. 2014 Jan 1; 24(1):245-8. https://doi.org/10.1016/j.bmcl.2013.11.029

 

 

 

Corresponding Author:

[1]* Nagaraj N Durgadasheemi, Pharmaceutical Chemistry, R R College of Pharmacy, Chikkabanavar, Bengaluru-560090 Karnataka, India,                                                              E-mail address: nag11.nd@gmail.com Tel: + 91-9916209962

2*Shivanand Kolageri, Pharmaceutical Chemistry, BLDEA’s SSM College of Pharmacy and Research Centre, Vijayapur-586103, Karnataka, India,                                                                    E-mail address: shivanandkolageri1996@gmail.com  Tel: + 91-8904312073